HK Stock Market Move | LEADS BIOLABS-B(09887) rises over 7% as abstracts of 6 studies are published, demonstrating differentiated efficacy and long-tail survival advantage.

LEADS BIOLABS-B(09887) rose over 7%, up 7.02% as of press time to HK$44.2, with turnover of HK$20.5967 million. On the news front, on October 19, Leads Biolabs announced that full abstracts of six studies on its self-developed LBL-024 (opapatusomab, an anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (a GPRC5D/CD3 bispecific T-cell engager, TCE) have been published on the official website of the 2026 ESMO Annual Meeting. The data collectively present the trend of durable responses and long-tail survival benefits of LBL-024 across multiple immune "cold tumors," supporting its potential as a pan-tumor therapy and highlighting the differentiated capabilities of the company's X-body and TCE technology platforms. It is worth noting that three studies of LBL-024 and LBL-034 were selected for preferred oral presentations at the 2026 ESMO, with one study selected as a Late-Breaking Abstract (LBA). Detailed and updated data from these studies will be released during the oral presentation sessions at the 2026 ESMO.